Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen Inc (AMGN) and Regulus (RGLS)


Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen Inc (NASDAQ:AMGN) and Regulus (NASDAQ:RGLS).

Amgen Inc (AMGN)

Mizuho Securities analyst Salim Syed maintained a Buy rating on Amgen Inc on July 6 and set a price target of $200. The company’s shares opened today at $194.17.

According to TipRanks.com, Syed is a 3-star analyst with an average return of 5.4% and a 62.9% success rate. Syed covers the Healthcare sector, focusing on stocks such as Wave Life Sciences, Biogen Inc, and Celgene.

Amgen Inc has an analyst consensus of Strong Buy, with a price target consensus of $200.14, implying a 3.1% upside from current levels. In a report issued on June 22, Morgan Stanley also maintained a Buy rating on the stock with a $200 price target.

.

See today’s analyst top recommended stocks >>

Regulus (RGLS)

In a report issued on July 6, Alan Carr from Needham maintained a Hold rating on Regulus. The company’s shares opened today at $0.38, close to its 52-week low of $0.33.

Carr noted:

“Regulus announced yesterday that findings in a mouse RGLS4326 toxicity study have led to suspension of clinical development. No safety issues have reportedly been observed in Phase 1 SAD/ MAD trials or in a non-human primate toxicity study. Details not disclosed, but mgmt believes issue can be resolved w/ additional preclinical studies. Regulus had planned on initiating a Phase 2 trial in ADPKD in 2019. Separately, Regulus has also suspended recruitment activities for RG-012 Alport program in order to conserve cash. Mgmt is in process of renegotiating its agreement w/ collaborator Sanofi for more favorable terms. Regulus also announced a 60% workforce reduction, reducing burn by $20M annualized. Maintain HOLD, awaiting proof of concept w/ candidate from current pipeline.”

According to TipRanks.com, Carr is a 4-star analyst with an average return of 5.1% and a 43.5% success rate. Carr covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, ACADIA Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.

The word on The Street in general, suggests a Hold analyst consensus rating for Regulus with a $0.75 average price target, representing a 97.4% upside. In a report released today, Wedbush also downgraded the stock to Hold with a $1 price target.

.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts